BURLINGTON, Mass. – March 10, 2010 – InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company’s LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology (ACC). The meeting, named ACC.10 and i2 Summit, is being held from March 14 – 16, 2010 at the Georgia World Congress Center in Atlanta.  In addition to several oral presentations featuring LipiScan, InfraReDx has organized a “Meet the Experts” series of discussions at the Company’s booth (#254) in which leading cardiologists will highlight LipiScan’s capabilities in identifying and characterizing lipid core (fatty) plaque.

InfraReDx’s LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be “vulnerable plaque” that can rupture and form dangerous blood clots leading to coronary thrombosis. LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.

“One of the biggest challenges facing interventional cardiologists today is the ability to detect vulnerable coronary and fatty plaques,” said Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital. “As a result of improved imaging and diagnostic capabilities, however, physicians can now be armed with that information and are able to make important advances and improvements in patient care. This year’s ACC meeting provides us with a great opportunity to interact with our colleagues, share key learnings and discuss important steps forward.”

“We are pleased to be working so closely with these world renowned cardiology experts and leaders as they strive to improve patient care and we advance our LipiScan coronary imaging system,” said James E. Muller, M.D., founder and chief executive officer of InfraReDx. “Through our close collaborations with these physicians and specialists, we are continuing to increase our working knowledge, enhance our LipiScan system and, ultimately, to significantly improve the imaging capabilities for interventional cardiologists and their patients. We are looking forward to a productive conference and many lively discussions at our booth about advancing the current standard of cardiac care.”

The schedule of scientific sessions and “Meet the Experts” discussions to feature LipiScan is as follows.

ACC Scientific Sessions Highlighting LipiScan™ Coronary Imaging System:

Sunday, March 14:
8:00 a.m. – 9:30 a.m., Session #2092, Room B310
Session title: Imaging and Vulnerable Plaque
Presentation title: Association of Large Lipid Core Plaque Detected by Near Infrared Spectroscopy with Post Percutaneous Coronary Intervention Myocardial Infarction
Presenter: Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital

Tuesday, March 16
10:30 a.m. – Noon, Session #2629, Room B310
Session title: Vulnerable Plaque Update
Presentation title: Near-Infrared Spectroscopy
Presenter: James Goldstein, M.D., director of research and education, Division of Cardiology, William Beaumont Hospital

InfraReDx “Meet The Experts” series:

Sunday, March 14:
9:30 a.m. – 10:30 a.m., Exhibit Hall: Morning Break
“Increased Lipid Core Plaque in Women Undergoing Stenting”
Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Noon – 1:00 p.m., Exhibit Hall: ACC Lunch & Learn
“Lipid Core Plaque Modification”
Expert: Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital

1:00 p.m. – 2:00 p.m., Exhibit Hall: ACC Lunch & Learn
“LipiScan™ Clinical Experience; Identification of Bifurcation Lesions at Risk of Compromise”
Expert: Giora Weisz, M.D., director of clinical research, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center

3:30 p.m. – 4:30 p.m., Exhibit Hall: Poster Hour
“Pick the Peri-Stenting MI”
Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Monday, March 15:
9:30 a.m. – 10:30 a.m., InfraReDx Booth # 254
“Multi-Modality Imaging”
Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Noon – 1:00 p.m., InfraReDx Booth #254
“Stent Length Placement & Distal Embolization”
Expert: James Goldstein, M.D., director of research and education, Division of Cardiology, William Beaumont Hospital

1:00 p.m. – 2:00 p.m., InfraReDx Booth #254
“Peri-Stenting MI”
Expert: Emmanouil S. Brilakis, M.D., Ph.D., director of the cardiac catheterization laboratory, Dallas VA Medical Center

3:30 p.m. – 4:30 p.m., InfraReDx Booth #254
“PROSPECT Trial and the Vulnerable Plaque”
Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Tuesday, March 16
9:30 a.m. – 10:30 a.m., InfraReDx Booth #254
“Vulnerable Blood & Vulnerable Plaque; Coagulation Profiling & Plaque Morphology
Characterization”
Expert:  Paul A. Gurbel, M.D., director of cardiovascular research, Center for Thrombosis Research, Sinai Hospital of Baltimore

Noon – 1:00 p.m., InfraReDx Booth # 254
“Advances in Intra-coronary Imaging in the Past Year - NIR, IVUS, OCT and Others”
Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

About ACC.10 and i2 Summit 2010
The Annual Scientific Session of the American College of Cardiology (ACC) is the largest and foremost cardiovascular meeting, offering attainable, reliable and applicable learning solutions that help cardiovascular professionals turn knowledge into practice that saves and improves lives. The Annual Scientific Session delivers timely medical education leveraging innovative need-based learning methods. Together, ACC.10 and i2 Summit 2010 embody the College’s vision of building meetings with innovative solutions that assist the faculty to teach and audiences to learn.  For more information, visit http://acc10.acc.org/Pages/ACC2010Home.aspx.

About InfraReDx, Inc.
InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.

Contacts:
Media:
Keri Mattox
Pure Communications, Inc.
215.791.0105
keri@purecommunicationsinc.com

Company:
Jim Dillon
Vice President of Sales and Marketing.
781.345.9679
jdillon@infraredx.com

Source: InfraReDx, Inc.

One of the best defenses against heart attack and other life threatening health conditions is to lead a healthy lifestyle. Most people under estimate the positive effects that eating healthy and working out on a regular basis can have on your body. The best way to find a workout and diet plan that is right for you is by contacting your doctor. They will be able to assist you and find a plan that works for your body. So do not waste anymore time, take the necessary steps to work towards heart attack prevention today.

Understanding and being aware of different heart attack symptoms is important and can help to save your life. Symptoms of a heart attack vary amongst individuals and also between men and women. Below is a common list of heart attack symptoms:

• Chest Discomfort
• Discomfort in other areas of the upper body
• Shortness of breath
• Nausea
• Lightheadedness
• Breaking out in a cold sweat

For more information about heart attack symptoms contact your doctor. They will be able to assist you and come up with preventative measures that you can take to work towards heart attack prevention.

Did you know that heart disease is the number one killer of women in America? This is a scary but true fact about heart disease. Too many people feel heart disease is something that mainly affects men and is something women do not really need to worry about. That information is untrue.

One of the best ways to monitor heart disease is by having regular checkups with your doctor. They will be able to monitor your heart and provide the best treatments or recommendations for you.  So do not waste another moment contact your doctor today for more information.

BURLINGTON, Mass. - February 24, 2010 – InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world’s premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention. InfraReDx will be displaying its novel LipiScan™ Coronary Imaging System at booth #306 throughout the LUMEN meeting. InfraReDx will be available to discuss with attending clinical and interventional cardiologists, cardiac and vascular surgeons and other cardiovascular professionals LipiScan’s abilities in identifying and characterizing lipid core (fatty) plaques and the importance of this novel technology.

InfraReDx’s LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be “vulnerable plaque” that can rupture and form dangerous blood clots leading to coronary thrombosis.  LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.

LUMEN 2010 marks the third key educational symposium that the Company has participated in over the past month. InfraReDx was an active speaking and panel participant during the recent Cardiovascular Research Technologies (CRT) annual meeting in Washington, D.C., and live case demonstrations of the LipiScan system were a highlight of the Scottsdale Interventional Forum in Scottsdale, Arizona, earlier this month. InfraReDx will continue to showcase LipiScan at upcoming events and medical meetings, including the 59th Annual Scientific Sessions of the American College of Cardiology (ACC), taking place March 14-16 in Atlanta.

About InfraReDx, Inc.
InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.

About LUMEN 2010
LUMEN 2010 enables productive peer-to-peer discussions pertaining to establishing the best practices in the treatment of acute MI patients, including diagnosis and treatment options, giving them the practical knowledge, tools, and insight they need to improve patient care and quality of life. LUMEN 2010 will benefit clinical and interventional cardiologists, cardiac and vascular surgeons, emergency department staff, critical care nurses, cardiovascular laboratory technologists and nurses, paramedics, emergency medical technicians, and hospital administrators. For more information, please visit www.lumenami.com.

Contacts:
Media:
Keri Mattox
Pure Communications, Inc.
215.791.0105
keri@purecommunicationsinc.com

Company:
Jim Dillon
Vice President of Sales and Marketing.
781.345.9679
jdillon@infraredx.com

Source: InfraReDx, Inc.

BURLINGTON, Mass. - February 18, 2010 – InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company’s founder and chief executive officer, James E. Muller, M.D., will present and participate in a number of sessions and panel discussions during the annual Cardiovascular Research Technologies (CRT) 2010 meeting. CRT 2010, sponsored by Washington, D.C. based Washington Hospital Center, is being held February 21-23 at the city’s Omni Shoreham Hotel. Dr. Muller is an invited faculty member for this educational summit attended by interventional cardiologists and vascular medicine specialists. The capabilities of InfraReDx’s commercially available LipiScan™ Coronary Imaging System will be highlighted by Dr. Muller at the meeting and at the company’s exhibition booth, #210.

InfraReDx’s LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. In addition to the benefits of NIR, as currently integrated into the LipiScan system, Dr. Muller will also discuss the potential advantages of integrating intravascular ultrasound (IVUS) capabilities.

His presentation schedule during CRT 2010 is as follows:

Monday, February 22 – Emerging Technologies
Dr. Muller will speak during the Emerging Technologies Session presentation titled “Imaging”, which is scheduled for February 22 from 8:00 a.m. to 10:00 a.m. ET. As part of this presentation, he will discuss “Lipid Detection InfraReDx Technology Integrated with IVUS,” and will also participate in the panel session following formal remarks.

Monday, February 22 – Vulnerable Plaque Summit
Dr. Muller will join numerous world renowned Interventional Cardiologists presenting on the critical topic of vulnerable plaque and will be speaking during the Vulnerable Plaque Summit presentation titled “Invasive Imaging of Vulnerable Plaques II”, which runs on February 22 from 3:30 p.m. to 4:40 p.m. ET. As part of this presentation he will present an update on “Near Infrared Spectroscopy Technology,” and will also participate in the panel session following formal remarks.

Tuesday, February 23 – Atherosclerosis & Lipid Management
Dr. Muller will speak during the Atherosclerosis & Lipid Management session, as a participant in a debate titled “Identification of the Vulnerable Plaque: Critical Concept or Hype?” which is scheduled to begin at 10:30 a.m. ET.

Dr. Muller is a globally recognized expert on the subject of vulnerable plaques, a key field of study since he and colleagues first introduced the concept in 1989. Dr. Muller’s work, and that of InfraReDx, is focused on lipid (fatty) core plaques known to rupture and form dangerous blood clots, leading to heart attacks.  These vulnerable plaques are widely considered to be responsible for a significant number of stenting post-procedure complications and are believed to be the primary cause of acute cardiac events and sudden cardiac death, the leading cause of death in the developed world.

About InfraReDx, Inc.
InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.

About CRT 2010
Cardiovascular Research Technologies (CRT) 2010, is a multi-modular meeting that focuses on the advances and changes in the field of cardiovascular medicine. With the significant incidence and prevalence of coronary and peripheral artery disease in the United States, it is essential for healthcare professionals to stay abreast of the developments in this field. CRT 2010 attendees will include cardiologists, basic scientists, vascular medicine specialists, cardiothoracic surgeons, nurses, technologists and other health care professionals with a special interest in the field of interventional and vascular medicine. CRT 2010 is being held by Washington, D.C. based Washington Hospital Center, an accredited Continuing Medical Education facility. The meeting will provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes. For more information, please visit www.crtmeeting.org.

Contacts:

Media:
Keri Mattox
Pure Communications, Inc.
215.791.0105
keri@purecommunicationsinc.com

Company:
Jim Dillon
Vice President of Sales and Marketing
781.345.9679
jdillon@infraredx.com

It has been known for some time that following a healthy diet is crucial for your heart and overall health of your body. Recent reports are confirming that a healthy diet is one of the best ways to fight heart disease.

Eating healthy is beneficial to your body in so many ways. The next time you go grocery shopping make sure to take a look at the label on the item you are purchasing and look for the following information:

• Serving Size - Check to see the size of a single serving and how many servings are in the package
• Check the total Calories per serving- Portion sizes often are not what you think, check to see how much food you are really consuming
• Check to make sure you are getting enough nutrients - You want to get 100 percent of the fiber, vitamins and other nutrients you need every day
• Limit certain nutrients- Make sure to limit your that amount of saturated fat and trans fat you consume each day

For more information about a diet plan that works for you and other heart attack prevention steps you can take contact your doctor today.

- Live Case Procedure to Demonstrate Capabilities of Novel Coronary Imaging System -

BURLINGTON, Mass. - February 11, 2010 – InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased tissues, today announced that its commercially available LipiScan™ Coronary Imaging System will be featured at the Scottsdale Interventional Forum, an international conference for Interventional Cardiologists and other healthcare professionals. The Forum is being held February 11-13 at the Scottsdale Westin Kierland Resort in conjunction with the Scottsdale Healthcare Shea Medical Center. David G. Rizik, M.D., Scottsdale Healthcare Medical Director of Invasive Cardiology, will perform “live case” demonstrations of the LipiScan system, to be broadcast at the Forum on Thursday and Friday, February 11th and 12th at 9:30 a.m. local time.

InfraReDx’s LipiScan system – the only FDA cleared product to detect lipid core plaque - utilizes catheter-based near-infrared (NIR) spectroscopy to identify and assess the composition of intracoronary plaques within artery walls that cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms.

“The ability to detect vulnerable coronary and fatty plaques using the LipiScan technology is of great interest to the Interventional Cardiology community and it represents an important advance in patient care,” said Dr. Rizik. “With the information provided by LipiScan on the chemical makeup of coronary artery plaques, which I look forward to demonstrating via the “live case” broadcasts, our practice is better equipped to identify the coronary plaques of particular concern - those with lipid cores. As a result of this improved imaging and robust diagnostic capability, we are better prepared to characterize patients’ plaques, reduce stenting complications, and ultimately determine the most appropriate treatment for patients with coronary artery disease.”

Lipid core-containing plaque is believed to be “vulnerable plaque”, or fatty plaque that can rupture and form dangerous blood clots. Vulnerable coronary artery plaque is widely considered to be the primary cause of acute coronary events (sudden cardiac deaths, strokes, non-fatal heart attacks), the leading cause of death in the developed world. The LipiScan system has been used in more than 800 patients at approximately 20 cardiovascular healthcare centers nationwide.

“We are very pleased that Dr. Rizik and Scottsdale Healthcare are successfully utilizing our near infrared LipiScan system, and demonstrating its unique capabilities at this key educational Forum,” stated James E. Muller, M.D., founder and Chief Executive Officer of InfraReDx. “We are proud of this technology and the benefits it currently offers the Interventional Cardiology community.”

About InfraReDx, Inc.
InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.

About the Scottsdale Interventional Forum
The annual Scottsdale Interventional Forum strives to provide comprehensive knowledge of the leading trends and best practices in cardiovascular disease therapies for cardiologists, industry professionals, nurses, technologists and other health professionals with specific interest in Interventional Cardiology. For details visit http://www.mocerimgmt.com/scottsdale2010/index.php.

Contacts:
Media:
Keri Mattox
Pure Communications, Inc.
215.791.0105

keri@purecommunicationsinc.com

Company:
Jim Dillon
Vice President of Sales and Marketing.
781.345.9679
jdillon@infraredx.com

Recent reports have found that women with gout are at a greater risk for heart attack than men who suffer from the disease. Gout is one of the most painful forms of arthritis. It occurs when too much uric acid builds up in the body. For most individuals the first attack of gout occurs in the big toe. The attack often wakes a person from sleep. The toe is very sore, red, warm, and swollen. Gout can also cause:

• Pain
• Swelling
• Redness
• Heat
• Stiffness in joints.

In the past research has proven that men who suffer from the disease are at a higher risk for heart attack but little information was known about the effects of the disease on women. Recent reports confirm that women who suffer from grout have a much higher risk of having a heart attack than men. If you have any question about gout or any other heart attack causes contact your doctor for more information today.

A heart attack can occur for a variety of reasons. The best way to prevent a heart attack is by having regular check ups with your doctor and by trying to live a healthy lifestyle.  Below are some common factors that can contribute to an increased risk for heart attack:

• persons with inherited hypertension (high blood pressure)
• persons with a family history of heart disease (especially with onset before age 55)
• persons with type 1 diabetes
• people who are under a lot of stress
• people who drink too much alcohol
• persons overweight by 30 percent or more
• persons who eat a diet high in saturated fat

If you feel you have a higher risk for any of these heart attack causes contact your doctor for more information.